Match tier
Listed
Presence
Current · Arkansas
Last published
2024
Sources
OpenAlex · ORCID
Refreshed
2026-10-06
W
William T. Bellamy
High Impact
Chair of the Department of Radiation and Imaging Studies
Also affiliated: University of Southern California (2005); City Of Hope National Medical Center (2005); University of Arizona (1988–2006); University of South Florida (2004); University of Arkansas Medical Center (2017); Moffitt Cancer Center (2004–2006); University of Illinois Chicago (2005); City of Hope (2005); Ventana Research Corporation (United States) (2000); University of Virginia Medical Center (1983); Environmental Education Exchange (2000); University of Arizona Cancer Center (1988–2001); University of Virginia (1982); University of Rochester (2005); University of Cincinnati (2000); University of California, Davis (2005)
30 h-index
67 pubs
4,695 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
William Bellamy is a researcher at the University of Arkansas for Medical Sciences with a focus on disease mechanisms and microbial infections. His work has led to 93 total publications, which have been cited approximately 4,756 times, contributing to an h-index of 30. Bellamy is recognized as a highly cited researcher. His recent publication in 2024 investigates the role of plasmid-encoded genes in the enzootic cycle of *Borrelia burgdorferi*. He has collaborated with colleagues including Jon S. Blevins, Brendan P. Moore, and Nora E. Gibbons, all from the University of Arkansas for Medical Sciences, on shared publications.
Metrics
- h-index: 30
- Publications: 67
- Citations: 4,695
Positions
-
Chair of the Department of Radiation and Imaging Studies publications 2006–2024University of Arkansas for Medical Sciences Institution web page
Selected Publications
-
The plasmid-encoded members of paralogous gene family 52 are dispensable to the enzootic cycle of Borrelia burgdorferi (2024)
-
Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases (2020)
-
ALK Rearrangements Are Infrequent in Cellular Blue Nevus and Deep Penetrating Nevus (2018)
-
Short-Duration Rapid Chilling of Mastectomy Specimens Does Not Interfere With Breast Cancer Biomarker and Molecular Testing (2018)
-
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma (2017)
-
BB0238, a Presumed Tetratricopeptide Repeat-Containing Protein, Is Required during Borrelia burgdorferi Mammalian Infection (2014)
-
Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis (2014)
-
Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients (2014)
-
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy (2012)
-
Use of Xylitol To Enhance the Therapeutic Efficacy of Polymethylmethacrylate-Based Antibiotic Therapy in Treatment of Chronic Osteomyelitis (2012)
-
Evaluation of Dynamic [18F]-FDG-PET Imaging for the Detection of Acute Post-Surgical Bone Infection (2012)
-
Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma (2011)
-
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial (2011)
-
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108 (2009)
-
Expression of Myeloma-Specific Markers in Bone Marrow Spicules Using a Novel Immunohistochemical Technique (2008)
Collaboration Network
Top Collaborators
Bart Barlogie
University of Arkansas for Medical Sciences
6 shared publications
In database
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Expression of Myeloma-Specific Markers in Bone Marrow Spicules Using a Novel Immunohistochemical Technique
Showing 5 of 6 shared publications
Horace J. Spencer
University of Arkansas for Medical Sciences
4 shared publications
In database
- Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis
- Evaluation of Dynamic [18F]-FDG-PET Imaging for the Detection of Acute Post-Surgical Bone Infection
- Use of Xylitol To Enhance the Therapeutic Efficacy of Polymethylmethacrylate-Based Antibiotic Therapy in Treatment of Chronic Osteomyelitis
- BB0238, a Presumed Tetratricopeptide Repeat-Containing Protein, Is Required during Borrelia burgdorferi Mammalian Infection
Robert A. Skinner
University of Arkansas for Medical Sciences (US)
4 shared publications
- Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis
- Evaluation of Dynamic [18F]-FDG-PET Imaging for the Detection of Acute Post-Surgical Bone Infection
- Use of Xylitol To Enhance the Therapeutic Efficacy of Polymethylmethacrylate-Based Antibiotic Therapy in Treatment of Chronic Osteomyelitis
- BB0238, a Presumed Tetratricopeptide Repeat-Containing Protein, Is Required during Borrelia burgdorferi Mammalian Infection
Joshua Epstein
University of Arkansas for Medical Sciences (US)
4 shared publications
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma
Shmuel Yaccoby
University of Arkansas for Medical Sciences
4 shared publications
In database
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma
Frits van Rhee
University of Arkansas for Medical Sciences
4 shared publications
In database
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma
John D. Shaughnessy
University of Arkansas for Medical Sciences
3 shared publications
In database
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- Expression of Myeloma-Specific Markers in Bone Marrow Spicules Using a Novel Immunohistochemical Technique
Karen E. Beenken
University of Arkansas for Medical Sciences
3 shared publications
In database
- Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis
- Evaluation of Dynamic [18F]-FDG-PET Imaging for the Detection of Acute Post-Surgical Bone Infection
- Use of Xylitol To Enhance the Therapeutic Efficacy of Polymethylmethacrylate-Based Antibiotic Therapy in Treatment of Chronic Osteomyelitis
Sandra G. McLaren
University of Arkansas for Medical Sciences (US)
3 shared publications
- Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis
- Evaluation of Dynamic [18F]-FDG-PET Imaging for the Detection of Acute Post-Surgical Bone Infection
- Use of Xylitol To Enhance the Therapeutic Efficacy of Polymethylmethacrylate-Based Antibiotic Therapy in Treatment of Chronic Osteomyelitis
Mark S. Smeltzer
University of Arkansas for Medical Sciences
3 shared publications
In database
- Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis
- Evaluation of Dynamic [18F]-FDG-PET Imaging for the Detection of Acute Post-Surgical Bone Infection
- Use of Xylitol To Enhance the Therapeutic Efficacy of Polymethylmethacrylate-Based Antibiotic Therapy in Treatment of Chronic Osteomyelitis
Susann M. Szmania
University of Arkansas for Medical Sciences (US)
3 shared publications
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma
Tarun K. Garg
University of Arkansas for Medical Sciences (US)
3 shared publications
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma
Amy D Greenway
University of Arkansas for Medical Sciences
3 shared publications
In database
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma
Joshuah D Lingo
University of Arkansas for Medical Sciences (US)
3 shared publications
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma
Bijay Nair
University of Arkansas for Medical Sciences (US)
3 shared publications
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma
Similar Researchers
Based on overlapping research topics
Kristi Reed
University of Arkansas for Medical Sciences
Microbial infections and disease research
Disease Mechanisms Research
Host-Pathogen Interactions
Jennifer R. Thompson
University of Arkansas for Medical Sciences
Microbial infections and disease research
Disease Mechanisms Research
Host-Pathogen Interactions
C K Beck
University of Arkansas for Medical Sciences
Microbial infections and disease research
Disease Mechanisms Research
Host-Pathogen Interactions
Cara Pirani
Arkansas State University
Microbial infections and disease research
Disease Mechanisms Research
Host-Pathogen Interactions
Megan E. Rosa
University of Arkansas at Fayetteville
Microbial infections and disease research
Host-Pathogen Interactions
Genomics and Phylogenetic Studies
Katherine E. Luhring
University of Arkansas at Fayetteville
Microbial infections and disease research
Host-Pathogen Interactions
Genomics and Phylogenetic Studies